According to GuruFocus list of 3-year lows; Cenovus Energy Inc, Altera Corp, Boardwalk Pipeline Partners LP, and RetailMeNot Inc hae all reached their 3-year lows.
Cenovus Energy, Inc. (CVE) Reached the 3-year Low of $28.17
The prices of Cenovus Energy, Inc. (CVE) shares have declined to close to the 3-year low of $28.17, which is 33.3% off the 3-year high of $40.73.
Cenovus Energy, Inc. has a market cap of $21.29 billion; its shares were traded at around $28.17 with a P/E ratio of 37.10 and P/S ratio of 1.26. The dividend yield of Cenovus Energy, Inc. stocks is 3.32%.
Cenovus Energy has released its third quarter 2013 results. For this quarter, operating cash flow was $1.1 billion, a 12% decrease compared with the same quarter of 2012. Operating earnings were $313 million ($0.41 per diluted share), a 28% decrease over last year. Cenovus’ net earnings were $370 million compared with $289 million the prior year quarter.
3 Gurus Kept Po sitions in CVE Unchanged or Slightly Adjusted: Jean-Marie Eveillard owns 20,263,412 shares as of 09/30/2013.Third Avenue Management owns 19,200 shares as of 09/30/2013. Bill Nygren owns 3,930,000 shares as of 09/30/2013.
5 Best International Stocks To Own For 2014: Euro/Swiss(RF)
Regions Financial Corporation operates as the holding company for Regions Bank that provides a range of commercial, retail, and mortgage banking services in the United States. It offers various deposit products, including savings and transaction accounts; demand deposit accounts; money market accounts; and time deposits, such as certificate of deposits and individual retirement accounts. The company?s loan portfolio comprises commercial loans, such as commercial and industrial, and owner occupied commercial real estate mortgage and construction loans; investor real estate loans, including commercial real estate mortgage and construction loans; and consumer loans, which consist of residential first mortgage, home equity, indirect, consumer credit card, and other consumer loans. Regions Financial Corporation, through other subsidiaries, also provides regional brokerage and investment banking products and services, such as securities brokerage, trust, asset management, finan cial planning, mutual funds, securities underwriting, sales and trading, and investment banking services for individual and institutional investors; and insurance brokerage services for various lines of personal and commercial insurance comprising property, casualty, life, health, and accident. In addition, the company offers credit-related insurance, including title, term life, credit life, environmental, crop, and mortgage insurance; debt cancellation products; and equipment financing products primary for commercial clients. As of December 31, 2011, it operated approximately 2,100 ATMs and 1,726 banking offices in Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas, and Virginia. The company was founded in 1970 and is headquartered in Birmingham, Alabama.
- [By Lauren Pollock]
Regions Financial Corp.(RF) said its fourth-quarter profit fell 14% as the Birmingham, Ala.-based lender continues to fix its loan portfolio through debt restructuring. Revenue topped views.
- [By Monica Gerson]
Regions Financial (NYSE: RF) is expected to report its Q4 earnings at $0.20 per share on revenue of $1.31 billion.
Unilever plc (NYSE: UL) is estimated to report its Q4 results.
- [By Sue Chang]
Regions Financial Corp. (RF) is likely to post fourth-quarter earnings of 20 cents a share.
5 Best International Stocks To Own For 2014: Athersys Inc.(ATHX)
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
- [By Sean Williams]
What: Shares of Athersys (NASDAQ: ATHX ) , a clinical-stage biotechnology company focused on regenerative medicine, advanced as much as 10% after announcing that it had been granted three new patents for its stem cell and regenerative technologies in Japan.
- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Tuesday’s session are 3M Co.(MMM), Boeing Co.(BA) and Athersys Inc.(ATHX)
3M raised its quarterly dividend by 35%, as the company continued its effort to consistently boost its payouts to shareholders. 3M–whose products include Scotch tape, Nexcare bandages and Post-it Notes–is known as a reliable profit machine. Dividends have increased annually in each of the past 55 years. Shares rose 2.8% to $131 premarket.
- [By Roberto Pedone]
Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 4% to $1.79 in Thursday’s trading session.
Thursday’s Range: $1.68-$1.80
52-Week Range: $0.95-$2.42
Thursday’s Volume: 270,000
Three-Month Average Volume: 323,188
From a technical perspective, ATHX bounced notably higher here right off its 50-day moving average of $1.67 with decent upside volume. This stock recently pulled back from $1.99 to its 50-day at $1.67. Shares of ATHX may now be down with that pullback, since the stock is starting to trend higher and move within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.90 to $1.99 with high volume.
Traders should now look for long-biased trades in ATHX as long as it’s trending above its 50-day at $1.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 323,188 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $2.16 to $2.25. Any high-volume move above those levels will put its 52-week high at $2.42 into range for shares of ATHX.
5 Best International Stocks To Own For 2014: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company’s SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company’s electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators incl ude University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int’l.
The Company’s synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company’s synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deo xyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company’s synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company’s SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines : preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body’s natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females’ a ges 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio’s PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.
The Company’s VGX-3400X targe ts H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season’s new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
- [By Jake L’Ecuyer]
Inovio Pharmaceuticals (NYSE: INO) was also up, gaining 10.53 percent to $3.57 after the company received the “Best Theraputic Vaccine” award at the World Vaccine Congress after the close Wednesday.
- [By MONEYMORNING]
Inovio Zooms: We recommended biotech Inovio Inc. (NYSE: INO) at 71 cents a share back on Feb. 1, 2013, and have re-recommended it a number of times since. With their 15.2% gain yesterday, the shares are now at $3.71, up 414% from where we first told you about them – and we believe there’s more to come. In fact, we’ll be bringing you an interesting update on this company very soon. Inovio is one of 24 recommendations that have doubled or better since we launched Private Briefing back in August 2011
- [By Jake L’Ecuyer]
Equities Trading DOWN
Shares of Inovio Pharmaceuticals (NYSE: INO) were down on Friday’s session, falling 13.28 percent to $2.488 despite seemingly little news on the company.
5 Best International Stocks To Own For 2014: Golar LNG Limited(GLNG)
Golar LNG Limited, a mid-stream liquefied natural gas (LNG) company, engages in the transportation, regasification, and liquefaction and trading of LNG. It acquires, owns, operates, and charters LNG carriers and floating storage regasification units (FSRUs). As of March 31, 2011, the company had a fleet of 12 vessels, including 8 LNG carriers and 4 FSRUs; and a 50% equity interest in 1 vessel. Golar LNG Limited was founded in 1946 and is headquartered in Hamilton, Bermuda.
- [By Eric Volkman]
Golar LNG (NASDAQ: GLNG ) isn’t full of hot air when it comes to dividend pronouncements. The company has declared its latest quarterly distribution, which amounts to $0.45 per share to be paid “on or about” June 27 to shareholders of record as of June 13. That amount is a 6% improvement over the previous two disbursements of $0.425 apiece, both of which were paid simultaneously last December.
- [By Rick Munarriz]
Golar LNG (NASDAQ: GLNG ) is also a gusher. The liquefied natural gas transporter is increasing its quarterly rate by 6% to $0.45 a share.
- [By Oil and Gas Investments Bulletin]
In this article I want to talk about permitting – but before that, remember that the first LNG proposal that will export BC and Alberta gas, the Douglas Channel project with Golar (GLNG), is so small at 0.2 bcf/d that it doesn’t need all this permitting.
5 Best International Stocks To Own For 2014: Banro Corp (BAA)
Banro Corporation (Banro) is a Canada-based gold exploration company. The Company holds, through four wholly owned subsidiaries, a 100% interest in four gold properties, which are known as Twangiza, Namoya, Lugushwa and Kamituga. These properties are covered by a total of 13 exploitation permits and are found along the 210 kilometer-long Twangiza-Namoya gold belt in the South Kivu and Maniema Provinces of eastern Democratic Republic of the Congo (DRC). The Company also holds 14 exploration permits covering an aggregate of 2,638 square kilometers. Its 10 of the permits are located in the vicinity of the Company’s Twangiza property and four are located in the vicinity of the Company’s Namoya property. During the year ended December 31, 2011, the Company was engaged in the construction of the Company’s Twangiza Phase I oxide mine, and continued its exploration activities at its Twangiza, Namoya and Lugushwa properties. Advisors’ Opinion:
- [By Anthony Mirhaydari]
I’ve added shares of BVN to my Edge Letter Sample Portfolio.
Breakout Gold Stocks to Buy: Banro (BAA)
Click to Enlarge Banro (BAA) is a gold mining outfit with operations in the Democratic Republic of the Congo. The company recently announced a 15% increase in gold production in the fourth quarter thanks to expansion and efficiency gains at its Twangiza facility.
- [By Bryan Murphy]
Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill…CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an “almost” small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market’s tumble, but because of it.
- [By Bryan Murphy]
With the weekend just around the corner – and with folks looking to close the books on what’s been a miserable week – most traders have already closed shop and gone home. Big mistake. Some of the best trades I’ve ever found were uncovered when nobody else cared, or was interested. Enter Banro Corporation (NYSEMKT:BAA)… a name I stumbled cross today when few other were even looking. I think BAA could be an explosive bullish mover over the course of the next few weeks. Though I don’t want to get married to it, I sure wouldn’t mind dating it for a while.